Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025


HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025.

Read more:
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

Related Posts